Bioregulator Peptides Explained: The Khavinson Peptides From Epitalon to Pinealon

Most research peptides were designed in Western pharmaceutical laboratories or universities. The bioregulator peptides have a very different story. They emerged from a Soviet military medical programme in the 1970s, grew into a Russian research institute dedicated to ageing, and produced a family of tiny peptides, often just two to four amino acids long, that their developers believe act directly on the genes of specific tissues. Their best-known members, Epitalon and Pinealon, are now studied worldwide, and “Khavinson peptides” and “bioregulator peptides” have become popular searches.

This guide explains what bioregulator peptides are, where they came from, how they are proposed to work, what the research has found, what its limitations are, and how the individual peptides differ. It is an educational overview of research findings, not medical advice. Crown Peptides supplies Epitalon and Pinealon for laboratory research use only.

The Short Answer

Bioregulator peptides are very short peptides, typically two to four amino acids, developed mainly by Vladimir Khavinson and colleagues in Saint Petersburg. Each was originally identified from, or designed to mimic, extracts of a particular organ, such as the pineal gland, thymus or brain. Their developers propose that they enter cells, reach the nucleus and interact with DNA and chromatin to regulate the activity of genes in the tissue they are associated with, helping to restore function that declines with age. Much of the research comes from the Saint Petersburg group, and independent replication is more limited.

Where Bioregulators Came From

A military medical programme

In the early 1970s, Vladimir Khavinson and Vyacheslav Morozov, working at the Military Medical Academy in Leningrad, began investigating whether extracts from animal organs could protect and restore the function of the corresponding human organs, with the aim of maintaining the health of military personnel under extreme conditions, including radiation exposure. Their first products were complex extracts of polypeptides from organs such as the thymus and the pineal gland.

From extracts to extracts’ secrets

Two of those extracts became well known in Russia: thymalin, from the thymus, and epithalamin, from the pineal gland. Both were reported in Russian research to have effects on immune function and on ageing-related measures. The next step was to find out which small components of the extracts were responsible.

The synthetic short peptides

By analysing the amino acid composition of the extracts, the researchers designed short synthetic peptides intended to reproduce their activity. Epitalon, Ala-Glu-Asp-Gly, was designed from the composition of epithalamin. Thymogen and other short peptides followed from thymus research. Pinealon, Glu-Asp-Arg, was later developed for the nervous system.

An institute for ageing

In 1992, the Saint Petersburg Institute of Bioregulation and Gerontology was established, with Khavinson as its director, to study these peptides in ageing. Over the following decades, the institute and collaborators published a large body of research on bioregulator peptides in cells, animals and people.

Russian Peptide Science More Broadly

Bioregulators are not the only research peptides with Russian origins, and it helps to distinguish them. Semax and Selank come from a separate programme at the Institute of Molecular Genetics in Moscow, led by Nikolai Myasoedov. Those peptides are seven amino acids long, built from fragments of the hormone ACTH and the immune peptide tuftsin with a protective proline-glycine-proline tail, and they are proposed to act through receptors and neurotrophic signalling rather than directly on DNA. The Saint Petersburg bioregulators are shorter, designed from organ extracts and proposed to act on the genome. Both programmes reflect a strong tradition of peptide research in Russia, where several peptides were registered as medicines decades before attracting interest elsewhere. Our article Semax vs Selank covers the Moscow peptides.

Two Types of Bioregulator

The Saint Petersburg researchers distinguish two broad kinds of product.

Extract-based bioregulators

These are complexes of peptides extracted from animal organs, such as thymalin and epithalamin. Their composition is complex and can vary with the source material.

Synthetic short peptides

These are single, defined peptide sequences made by chemical synthesis, such as Epitalon and Pinealon. Because they are defined molecules, they can be made to a consistent standard and verified by analysis, which makes them far more suitable for controlled research. The research peptides supplied by Crown Peptides are of this kind.

The Proposed Mechanism: Peptides That Talk to Genes

The core idea

The central and most distinctive claim of bioregulator research is that these very short peptides can enter cells, reach the nucleus and interact directly with DNA and with the proteins that package it, influencing which genes are switched on. This is very different from how most peptides work, by binding receptors on the outside of cells.

The systematic review

A 2021 systematic review in Molecules by Khavinson and colleagues set out the evidence for this idea (PMID: 34834147, PMC8619776). It described research proposing that short peptides can penetrate cells and nuclei, bind specific DNA sequences in gene promoter regions and interact with histone proteins, and in doing so influence gene expression and epigenetic regulation, including the patterns of chemical marks that control genes.

Why short peptides might be able to do this

Very small peptides are more likely than large ones to cross membranes, including through the transporters cells use to absorb di- and tripeptides. Their small size also makes them candidates for fitting into grooves on the DNA double helix. Those properties provide a plausible basis for the proposed mechanism, although the detailed evidence comes largely from the developers’ own work.

Tissue specificity

A further claim is that each peptide acts preferentially on the tissue it is associated with, the pineal peptide on pineal-related functions, the brain peptide on neurons and so on. The mechanism for that specificity is not fully understood and remains one of the open questions.

Epitalon: The Pineal Bioregulator

Epitalon is the best-known bioregulator and the most studied outside Russia.

Telomeres and telomerase

In a 2003 study, Khavinson and colleagues reported that Epitalon induced telomerase activity and lengthened telomeres in human fetal fibroblasts, cells that normally lack active telomerase (PMID: 12937682). A follow-up study found treated cells continued dividing well beyond the point at which untreated cells stopped (PMID: 15455129).

Lifespan in mice

In a lifetime study in female mice, Epitalon did not change average lifespan but increased the lifespan of the longest-lived animals and maximum lifespan, reduced chromosome abnormalities in bone marrow cells and reduced leukaemia incidence (PMID: 14501183).

Melatonin rhythms

In old rhesus monkeys, Epitalon restored the night-time rise in melatonin and the normal daily rhythm of cortisol (PMID: 14743609). See our Epitalon guide and Epitalon vs NAD+.

Why the Pineal Gland Was the Starting Point

The pineal gland, a tiny structure deep in the brain, produces melatonin and helps set the body’s daily rhythms. It was a natural focus for ageing research because its melatonin output declines with age and because disrupted rhythms are associated with many age-related changes. Early Russian research reported that pineal extracts influenced ageing measures in animals, and Epitalon was designed to capture that activity in a single defined molecule. The finding that Epitalon restored night-time melatonin in old monkeys fits this rationale, and the pineal connection gives both Epitalon and Pinealon, whose name reflects the same programme, their identity.

The Thymus and Immune Ageing

The thymus, where immune T cells mature, shrinks steadily from early adulthood, a process called thymic involution that contributes to weaker immune responses in older age. Thymus extracts were among the first bioregulator products, and thymalin became one of the best-known in Russia. The idea of restoring thymic function to counter immune ageing links bioregulator research to a much wider field. Thymosin alpha-1, a separate 28-amino-acid peptide first isolated from thymus extracts in the United States, is studied for immune modulation and is supplied by Crown Peptides as Thymosin Alpha-1. Our immune research guide covers that area.

Pinealon: The Brain Bioregulator

Pinealon, Glu-Asp-Arg, is a three-amino-acid peptide studied for protecting neurons.

Oxidative stress

In a 2011 study in Rejuvenation Research, Pinealon reduced reactive oxygen species and cell death in cells under oxidative stress, and its effects on the cell cycle led the authors to propose that it interacts directly with the genome (PMID: 21978084).

Dendritic spines

In a 2017 study, Pinealon increased mature dendritic spines, the structures neurons use to form lasting connections, by 71% in mouse hippocampal neurons exposed to amyloid, restoring them to normal levels (PMID: 28853087).

Human neurons from elderly donors

In a 2024 study using neurons made directly from elderly donors’ skin cells, Pinealon promoted dendrite growth and reduced oxidative DNA damage (PMID: 39518916, PMC11546785). See our Pinealon guide and Pinealon and DNA.

The Wider Bioregulator Family

The Saint Petersburg group has described many other short peptides associated with different tissues, including peptides linked to the thymus, blood vessels, liver, kidneys, eyes, cartilage and other organs, often sold in Russia under various names as supplements. Their research bases vary greatly, and many have been studied mainly in the developers’ own laboratories. Crown Peptides currently supplies Epitalon and Pinealon, the two bioregulators with the broadest research interest.

Epigenetics: Why the Idea Has Gained Attention

When bioregulator research began, the idea that small molecules could adjust gene activity without changing DNA sequences was unfamiliar. Today, epigenetics, the study of chemical marks on DNA and histones that control which genes are active, is one of the most important fields in biology. Researchers now know that epigenetic patterns shift with age, and “epigenetic clocks” based on these patterns can estimate biological age. That context has made the bioregulator proposal, short peptides influencing epigenetic regulation, far more interesting to mainstream scientists than it once was, because it offers a possible link between a simple molecule and one of the central processes of ageing. It also means the proposal can now be tested with powerful modern tools.

How Bioregulator Studies Compare With Other Peptide Research

Compared with most research peptides, bioregulators are unusual in several ways. They are shorter than almost any other studied peptide. Their proposed mechanism involves the nucleus rather than cell-surface receptors. Their research programme is older, stretching back five decades, and includes long-term animal lifespan studies that few other peptide programmes have attempted. But their research is also more concentrated in a single group than, for example, the research on BPC-157 or GHK-Cu, which, while also dominated by particular laboratories, has attracted more independent work. Placing bioregulators in this context helps researchers judge where the evidence is strong and where it most needs strengthening.

Strengths and Limitations of the Research

Strengths

The bioregulator programme has produced a very large body of research over five decades, across cells, animals and people, including long-term animal studies that few other peptide programmes have attempted. Its central idea, that short peptides can regulate genes directly, is scientifically interesting and has been increasingly explored with modern molecular techniques. Newer studies, such as the 2024 work on neurons from elderly donors, use advanced models.

Limitations

Most of the research comes from one institute and its close collaborators, and much was originally published in Russian journals less accessible to international scientists. Independent replication by unrelated laboratories is limited. Some human studies were small or lacked the rigorous controls expected in modern trials. And the proposed mechanism, while plausible, rests on evidence that other groups have not yet extensively confirmed. These are not reasons to dismiss the research, but they are reasons to treat it as promising and in need of independent confirmation.

Why that matters for researchers

For researchers, the bioregulator field offers both opportunity and responsibility: opportunity, because many of its most interesting claims have not yet been independently tested; responsibility, because testing them well requires verified material, rigorous controls and clear reporting.

Common Misconceptions About Bioregulators

“They are just amino acids”

Bioregulators are made of amino acids, but so is every peptide and protein. The claim is that specific short sequences have specific effects, and research using scrambled-sequence controls is the way to test that directly.

“They are the same as the extracts”

Synthetic short peptides such as Epitalon were designed from the composition of extracts, but they are single, defined molecules. The extracts are complex mixtures, and findings from one do not automatically apply to the other.

“The research proves they reverse ageing”

The research includes intriguing findings on telomeres, melatonin rhythms, neurons and lifespan in animals, but it does not show that bioregulators reverse ageing in people. Claims beyond the evidence are common online.

“Organ-specific means they only affect one organ”

The tissue-specificity idea is a proposal, not an established fact, and its mechanism is not fully understood. Studies measuring effects across several tissues are needed to test it.

How the Field Is Changing

Bioregulator research is gradually moving into the mainstream of international science. Newer studies use techniques such as gene expression profiling, molecular modelling of peptide-DNA interactions and advanced cell models, including neurons made directly from elderly people’s skin cells, as in the 2024 Pinealon study. More work is being published in international journals, and interest from independent laboratories is growing, partly because of the wider rise in epigenetic ageing research. That is exactly the direction the field needs: modern methods, open publication and independent testing of its central claims.

Designing Bioregulator Research

Test the mechanism directly

Because the central claim concerns gene regulation, the most valuable studies measure gene expression, chromatin changes and, where possible, direct peptide-DNA interaction, rather than only downstream outcomes.

Use sequence controls

With peptides this short, a scrambled-sequence control, containing the same amino acids in a different order, is essential to show that effects depend on the specific sequence rather than on amino acids in general.

Check cell entry

Labelled versions of the peptides can show whether and where they enter cells, directly testing a key step in the proposed mechanism.

Seek independent replication

Studies that replicate earlier findings using independently sourced, verified material are especially valuable in this field.

The Technical Breakdown: Short Peptides and the Genome

How short peptides enter cells

Cells absorb di- and tripeptides through proton-coupled transporters such as PepT1 and PepT2. Very short bioregulators may use these routes. Once inside, small molecules can pass through the pores in the nuclear envelope, which allow small molecules to move freely.

Binding DNA

The Saint Petersburg research proposes that short peptides bind specific sequences in the grooves of the DNA double helix, particularly in promoter regions that control whether genes are switched on. Charged amino acids such as glutamic acid, aspartic acid and arginine, prominent in Epitalon and Pinealon, could form interactions with DNA’s phosphate backbone and bases.

Histones and epigenetics

DNA is wound around histone proteins, and chemical marks on histones and DNA control how accessible genes are. The systematic review described research proposing that short peptides interact with histones and influence these epigenetic marks, which would allow them to change gene activity without changing the DNA sequence.

Why this is hard to prove

Showing that a tiny peptide binds a specific DNA sequence inside a living cell, and that this binding causes a particular change in gene activity, is technically demanding. It requires multiple independent methods, which is why independent confirmation matters so much.

Questions Worth Testing

The bioregulator field is full of claims that are testable with modern methods, which makes it an unusually rich area for new research. Does Epitalon induce telomerase in adult human cells, not only fetal ones, and in independent laboratories? Does Pinealon enter the nucleus of neurons, and does it bind the DNA sequences proposed? Do scrambled versions of these peptides lack their effects, as the sequence-specific model predicts? Are the effects truly tissue-specific? Do the lifespan findings in mice hold up in independent studies using verified material? Each of these questions could be answered with well-designed studies, and each answer would substantially strengthen, or reshape, understanding of the field.

Handling Very Short Peptides

Very short peptides such as Epitalon and Pinealon are generally stable as freeze-dried powders, but like all research peptides they should be stored cold, dry and away from light. Because they are so small, accurate weighing and concentration calculations matter. Our guides to peptide reconstitution, how long peptides last and the peptide calculator cover the practical side, and Bacteriostatic Water is available alongside.

Why Verified Material Matters

With peptides of three or four amino acids, the exact sequence is everything. A peptide with the same amino acids in a different order, or with a single substitution, is a different molecule, yet could look almost identical in a crude analysis. HPLC and mass spectrometry are essential to confirm purity and identity. Every batch of Epitalon and Pinealon supplied by Crown Peptides comes with a batch-specific certificate of analysis showing both. Published certificates are on our Lab Reports page, and our guides to peptide testing and reading a certificate of analysis explain the methods.

Related Compounds and Reading

For other compounds studied in ageing and brain research, see NAD+, MOTS-c, GHK-Cu, Semax, Selank and DSIP. Read best peptides for longevity research and best peptides for brain research, and browse the ageing and cellular research peptides category.

Bioregulator Questions, Answered

What are bioregulator peptides?

Very short peptides, typically two to four amino acids, developed mainly in Saint Petersburg, each associated with a particular tissue and proposed to regulate genes in that tissue.

Who is Vladimir Khavinson?

The Russian scientist who led the development of bioregulator peptides, beginning at the Military Medical Academy in Leningrad in the 1970s and later directing the Saint Petersburg Institute of Bioregulation and Gerontology.

What is the difference between Epitalon and Pinealon?

Epitalon is a four-amino-acid peptide studied mainly for telomeres, pineal function and ageing. Pinealon is a three-amino-acid peptide studied mainly for protecting neurons.

How do bioregulators work?

Their developers propose that they enter cells and the nucleus and interact with DNA and histones to regulate gene activity. The mechanism is plausible but has limited independent confirmation.

Where did the name Epitalon come from?

It reflects its origin in research on the epithalamus, the region of the brain that includes the pineal gland, and on the pineal extract epithalamin, from which its composition was designed.

Is Epitalon the same as Epithalon?

Yes. They are alternative spellings of the same tetrapeptide, Ala-Glu-Asp-Gly, used interchangeably in research and online.

Have bioregulators been studied in people?

Russian research reports human studies, including in older adults, but many were small or lacked the controls expected in modern trials. Well-designed, independent human trials are limited.

Which bioregulator is best for research?

It depends on the question. Epitalon suits research on telomeres, pineal function and ageing; Pinealon suits research on neurons, oxidative stress and brain ageing.

Are bioregulators legal in the UK?

Epitalon and Pinealon are not controlled drugs in the UK and are available as research materials. See are peptides legal in the UK.

What does “epigenetic” mean?

It refers to changes in gene activity that do not involve changes to the DNA sequence itself, such as chemical marks on DNA and on the histone proteins it is wound around.

Why are bioregulators so short?

Their developers designed them to capture the activity of organ extracts in the smallest possible molecules, and propose that small size helps them enter cells and interact with DNA.

Are Semax and Selank bioregulators?

Not in the Saint Petersburg sense. They come from a separate Moscow programme, are seven amino acids long and are proposed to act mainly through receptors and neurotrophic signalling rather than directly on DNA.

What is thymalin?

An extract-based bioregulator from the thymus, among the first products of the Leningrad programme, studied in Russia for immune function.

Why are scrambled-sequence controls important?

Because with such short peptides, the key question is whether effects depend on the exact sequence. A control with the same amino acids in a different order tests that directly.

Is bioregulator research independently confirmed?

Most research comes from the developers’ institute and collaborators. Independent replication is growing but limited, which is an important consideration when evaluating it.

Small Peptides, Big Ideas

The bioregulator peptides carry one of the boldest ideas in peptide science: that molecules just three or four amino acids long can reach the genome and help restore youthful patterns of gene activity in specific tissues. Five decades of Russian research, from military extracts to synthetic peptides and modern neuronal models, have built an intriguing case, and Epitalon and Pinealon have become the family’s international ambassadors. What the field needs now is exactly what good research always needs: verified material whose identity is beyond doubt, rigorous controls including scrambled sequences, open publication in international journals and, above all, independent replication by laboratories with no stake in the outcome. With those in place, the boldest claims about these tiny peptides can finally be confirmed, refined or set aside on the strength of the evidence.

Explore Epitalon and Pinealon from Crown Peptides, every batch HPLC and mass spectrometry verified and dispatched from the UK.